Posts Feed
Comments Feed

Archive for the 'Lupus' Category

Human Genome Sciences Completes Enrollment In Second Phase 3 Lymphostat-B(R) Trial

Sep 8th 2008Drug InformationLupus

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-BŪ (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006.

More: continued here

No Comments »

Medarex Announces Initiation Of Phase 2 Clinical Development Program For The Treatment Of Lupus

Sep 8th 2008Drug InformationLupus

Medarex, Inc. (Nasdaq: MEDX) announced that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex’s UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.

More: continued here

No Comments »

Seattle Genetics Initiates SGN-70 Phase I Clinical Trial - Investigational Therapy For Autoimmune Diseases

Sep 8th 2008Drug InformationLupus

Seattle Genetics, Inc. (Nasdaq:SGEN) announced that it has initiated a phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases. The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers.

More: continued here

No Comments »

« Prev - Next »

1